http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103169981-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4b1eac93fa8426bfd541c9e14e11860 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-12 |
| filingDate | 2011-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b43ef133ce2e4cdb4c497e863f9cb4da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bff7bcc8283216de7ca22015de20bd5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c5af6b13f175e4103f6d0812a33e0c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60ac29ff1518eaf880d6d06d817ceb80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2b9bc4de07dc6ddf31b28cf7b4ac29b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7de99a7ba94d9e0e1bc9095eaf2e765c |
| publicationDate | 2013-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103169981-A |
| titleOfInvention | Method for eliminating and reducing generation of accelerated blood clearance phenomenon |
| abstract | The invention belongs to medicine technical field, and discloses a method for eliminating and reducing generation of accelerated blood clearance phenomenon, which is characterized in that an injection interval of the PEGylation can be selected in a reasonable mode to eliminate or avoid the generation of accelerated blood clearance phenomenon. The injection interval of the PEGylation preparation is no less than 30 days, and preferably no less than 90 days, the PEGylation preparation is a clinical prevention, diagnosis or treatment preparation. The injection administration of the PEGylation preparation can reduce or completely eliminate the accelerated blood clearance phenomenon, thereby the generation of severe organ toxic response or analogous anaphylactic reaction can be avoided, and the pharmaceutical effect of the PEGylation preparation can be ensured. |
| priorityDate | 2011-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 362.